Dana-Farber Cancer Institute

Study finds promise in combined transplant/vaccine therapy for high-risk leukemia

Published in Vaccine Weekly, September 9th, 2009

BOSTON--Two of the most powerful approaches to cancer treatment -- a stem cell transplant and an immune system-stimulating vaccine -- appear to reinforce each other in patients with an aggressive, hard-to-control form of leukemia, Dana-Farber Cancer Institute scientists have found.

In a study to be published in the online early edition of the Proceedings of the National Academy of Sciences the week of Aug. 24, the researchers report that patients with high-risk acute myeloid leukemia (AML) or advanced myelodysplasia (a blood disorder) who received a cancer vaccine shortly after a stem cell transplant not only had few complications but also mounted a strong immune system...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2009-09-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry